Biomarker discovery and development for clinical research, diagnostics and therapy
monitoring in clinical trials have advanced rapidly in key areas of medicine—most notably …

Abstract Alzheimer's disease (AD), the most frequent cause of dementia, is escalating as a
global epidemic, and so far, there is neither cure nor treatment to alter its progression. The …

Background: Cerebral small vessel injury, including loss of endothelial tight junctions,
endothelial dysfunction, and blood-brain barrier breakdown, is an early and typical …

Emerging evidence suggests that small vessel disease (SVD) is a risk factor for clinical
dementia and may contribute to AD neuropathological changes. Watershed brain regions …

Cerebral small vessel disease is one of the most common causes of cognitive decline and
stroke. While several lines of evidence have established a relationship between …

There is growing evidence that air pollution is a risk factor for a number of
neurodegenerative diseases, most notably Alzheimer's (AD) and Parkinson's (PD). It is …

Growing evidence supports the use of plasma levels of tau phosphorylated at threonine 181,
amyloid-β, neurofilament light and glial fibrillary acidic protein as promising biomarkers for …

Including apolipoprotein E-ε4 (APOE-ε4) status and older age into consideration may
increase the accuracy of plasma Aβ42/Aβ40 detecting Aβ+ individuals, but the rationale …

Background and Purpose—Inflammation is involved in the pathogenesis of large artery
atherosclerosis, ischemic stroke, and Alzheimer dementia. However, the role of inflammation …

Background We assessed the feasibility of plasma Aβ42/Aβ40 determined using a novel
liquid chromatography-mass spectrometry method (LC-MS) as a useful biomarker of PET …